Fundamental Analysis of ENVERIC BIOSCIENCES INC(NASDAQ:ENVB) stock

Fundamental Rating

Overall ENVB gets a fundamental rating of 2 out of 10. We evaluated ENVB against 198 industry peers in the Pharmaceuticals industry. ENVB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ENVB does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

ENVB had negative earnings in the past year.

In the past year ENVB has reported a negative cash flow from operations.

ENVB had negative earnings in each of the past 5 years.

ENVB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -405.97%, ENVB is not doing good in the industry: 95.38% of the companies in the same industry are doing better.

ENVB has a worse Return On Equity (-892.28%) than 85.64% of its industry peers.

		Industry Rank	Sector Rank
ROA	-405.97%
ROE	-892.28%
ROIC	N/A

ROA(3y)-228.5%

ROA(5y)-175.33%

ROE(3y)-413.37%

ROE(5y)-299.5%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ENVB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, ENVB has more shares outstanding

ENVB has more shares outstanding than it did 5 years ago.

There is no outstanding debt for ENVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -42.03, we must say that ENVB is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -42.03, ENVB is not doing good in the industry: 90.26% of the companies in the same industry are doing better.

ENVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-42.03

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ENVB has a Current Ratio of 1.53. This is a normal value and indicates that ENVB is financially healthy and should not expect problems in meeting its short term obligations.

With a Current ratio value of 1.53, ENVB is not doing good in the industry: 75.90% of the companies in the same industry are doing better.

ENVB has a Quick Ratio of 1.53. This is a normal value and indicates that ENVB is financially healthy and should not expect problems in meeting its short term obligations.

ENVB's Quick ratio of 1.53 is on the low side compared to the rest of the industry. ENVB is outperformed by 68.72% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.53
Quick Ratio	1.53

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ENVB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.57%, which is quite impressive.

EPS 1Y (TTM)40.57%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q64.36%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

ENVB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.18% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y67.38%

EPS Next 2Y35.18%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENVB. In the last year negative earnings were reported.

Also next year ENVB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ENVB's earnings are expected to grow with 35.18% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.18%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ENVB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ENVERIC BIOSCIENCES INC

NASDAQ:ENVB (4/24/2024, 10:00:34 AM)

0.8959

0 (-0.17%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap6.53M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-405.97%
ROE	-892.28%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.53
Quick Ratio	1.53
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)40.57%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y67.38%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ENVERIC BIOSCIENCES INC (ENVB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens